Pedapati, Ernest V.
Mooney, Lindsey N.
Wu, Steve W.
Erickson, Craig A.
Sweeney, John A.
Shaffer, Rebecca C.
Horn, Paul S. http://orcid.org/0000-0002-4990-5754
Wink, Logan K.
Gilbert, Donald L.
Funding for this research was provided by:
American Academy of Child and Adolescent Psychiatry (Junior Investigator Award)
U.S. Department of Health & Human Services | National Institutes of Health (5K23MH112936)
Article History
Received: 24 April 2019
Revised: 23 September 2019
Accepted: 15 October 2019
First Online: 13 November 2019
Conflict of interest
: No author reports a conflict of interest with current submitted research paper. E.V.P. receives current and/or past research support by the NIH, American Academy of Child and Adolescent Psychiatry, and Cincinnati Children’s Hospital Research Foundation. He is a clinical trial site investigator for the Marcus Autism Center and Statking. He receives compensation for consulting for Proctor & Gamble, Eccrine Systems, and Autism Speaks. He receives textbook royalties from Springer. C.A.E. has received funding from Confluence Pharmaceuticals, Novartis, F. Hoffmann-La Roche Ltd., Seaside Therapeutics, Riovant Sciences, Inc., Fulcrum Therapeutics, Neuren Pharmaceuticals Ltd., Alcobra Pharmaceuticals, Neurotrope, Zynerba Pharmaceuticals, Inc., and Ovid Therapeutics Inc. to consult on trial design or development strategies and/or conduct clinical trials in neurodevelopmental disorders. C.A.E. is additionally the inventor or co-inventor on several patents held by Cincinnati Children’s Hospital Medical Center or Indiana University School of Medicine describing methods of treatment of neurodevelopmental disorders. L.K.W. has received consulting fees from Ovid Therapeutics, research funding from Cures within Reach, Roivant Sciences, Ovid Therapeutics, Autism Speaks, NIH/NICHD/NIMH. She has no conflicts of interest directly relating to this research. S.W.W. receives research support from NIH and Tourette Association of America. He is the site principal investigator for an ataxia-telangiectasia clinical trial sponsored by EryDel S.p.A. S.W.W. is also a consultant for Medtronic. D.L.G. has received honoraria and/or travel support from the Tourette Association of America/ Centers for Disease Control and Prevention, the American Academy of Pediatrics, the Child Neurology Society, the Texas Neurological Society. He has received compensation for expert testimony for the U.S. National Vaccine Injury Compensation Program, through the Department of Health and Human Services, and for the US Armed Services/US Attorney’s Office of VA. D.L.G. has received research support from the NIH (NIMH, NINDS). He has received funding for work as a clinical trial site investigator from Ecopipam Pharmaceuticals (clinical trial, Tourette Syndrome) and EryDel (clinical trial, Ataxia Telangiectasia). He has received book royalties from Elsevier and Wolters Kluwer. L.N.M., P.S.H., R.C.S., and J.A.S. have no conflicts of interest to disclose.